Background
Methods
Study design and participants
Treatment and dose modification
Assessment
Statistical analysis
Results
Patient characteristics
Number of patients (%) (N = 36) | |
---|---|
Age | |
Median (range) | 58 (21–74) |
≥ 65 years | 10 (27.8%) |
Sex | |
Male | 33 (91.7%) |
Female | 3 (8.3%) |
Hepatocellular carcinoma etiology | |
Hepatitis B | 26 (72.2%) |
Hepatitis C | 1 (2.8%) |
Alcoholic cirrhosis | 8 (22.2%) |
Other | 1(2.8%) |
Metastastic sites | |
Lung | 22 (61.1%) |
Lymph node | 11 (30.6%) |
Bone | 9 (25.0%) |
Other | 11 (30.6%) |
ECOG PS | |
0 | 23 (63.9%) |
1 | 13 (36.1%) |
2 | 0 (0.0%) |
Any prior therapy | |
Sorafenib | 31 (86.1%) |
Locoregional therapya | 31 (86.1%) |
AFP | |
< 200 ng/mL | 22 (61.1%) |
≥ 200 ng/mL | 14 (38.9%) |
PIVKA | |
< 400 mAU/mL | 17 (47.2%) |
≥ 400 mAU/mL | 19 (52.8%) |
Efficacy
Toxicity
All courses (total N = 36) | ||||
---|---|---|---|---|
Grade 1 | Grade 2 | Grade 3 | Total | |
Neutropeniaa | N/A | 6 (16.7%) | 5 (13.9%) | 11 (30.1%) |
Thrombocytopeniaa | N/A | 10 (27.8%) | 5 (13.9%) | 15 (41.7%) |
Bilirubina | N/A | 2 (5.6%) | 0 (0.0%) | 2 (5.6%) |
AST/ALTa | N/A | 1 (2.8%) | 1 (2.8%) | 2 (5.6%) |
Asthenia | 4 (11.1%) | 3 (8.3%) | 1 (2.8%) | 8 (22.2%) |
Anorexia | 10 (27.8%) | 2 (5.6%) | 0 (0.0%) | 12 (33.3%) |
Nausea | 13 (36.1%) | 0 (0.0%) | 0 (0.0%) | 13 (36.1%) |
Vomit | 5 (13.9%) | 0 (0.0%) | 0 (0.0%) | 5 (13.9%) |
Abdominal pain | 7 (19.4%) | 1 (2.8%) | 0 (0.0%) | 8 (22.2%) |
Stomatitis | 8 (22.2%) | 1 (2.8%) | 0 (0.0%) | 9 (25%) |
Diarrhea | 8 (22.2%) | 3 (8.3%) | 3 (8.3%) | 14 (38.9%) |
Constipation | 5 (13.9%) | 2 (5.6%) | 0 (0.0%) | 7 (19.4%) |
Sensory neuropathy | 14 (38.9%) | 4 (11.1%) | 1 (2.8%) | 19 (52.8%) |
Motor neuropathy | 0 (0.0%) | 1 (2.8%) | 0 (0.0%) | 1 (2.8%) |
Skin rash | 2 (5.6%) | 1 (2.8%) | 0 (0.0%) | 3 (8.3%) |